No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study - Hiransuthikul, Akarin; Thammajaruk, Narukjaporn; Kerr, Stephen; Janamnuaysook, Rena; Nonenoy, Siriporn; Hongchookiat, Piranun; Trichavaroj, Rapee; Tawon, Yardpiroon; Boonruang, Jakkrapatara; Teeratakulpisarn, Nipat; Cressey, Tim R.; Anderson, Peter L.; et al. (Journal of the International AIDS Society, 2025)
Keywords: Adenine - administration & dosage; Adenine - analogs & derivatives; Adenine - pharmacokinetics; Administration, Oral; Adult; Alanine; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - pharmacokinetics; Antiretroviral drugs; Cyproterone Acetate - administration & dosage; Cyproterone Acetate - pharmacokinetics; Drug dosages; Drug Interactions; drug−drug interactions; Emtricitabine - administration & dosage; Emtricitabine - pharmacokinetics; Endocrine therapy; Estradiol - administration & dosage; Estradiol - pharmacokinetics; Female; feminizing hormone therapy; HIV; HIV Infections - prevention & control; HIV prevention; Human immunodeficiency virus; Humans; Male; Middle Aged; Pharmacokinetics; Plasma; Pre-Exposure Prophylaxis - methods; pre‐exposure prophylaxis; Prophylaxis; Sample size; Tenofovir - administration & dosage; Tenofovir - analogs & derivatives; Tenofovir - pharmacokinetics; Testosterone; Thailand; Transgender Persons; transgender women; Women; Young Adult; Thailand; United States--US; Bangkok Thailand; pre‐exposure prophylaxis; HIV prevention; drug−drug interactions; Thailand; feminizing hormone therapy; transgender women